---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000089"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T06:05:03.072542+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma stockholders elect three Class II directors and ratify E&Y as auditor at 2023 annual meeting

## Summary
- Dawn Halkuff elected with 53.2M for, 4.4M withhold, 31.2M broker non-votes.
- John Johnson elected with 42.9M for, 14.7M withhold, 31.2M broker non-votes.
- Jeffrey Sherman elected with 51.3M for, 6.3M withhold, 31.2M broker non-votes.
- Ratification of Ernst & Young as auditor approved: 87.8M for, 0.8M against, 0.2M abstain.
- No other matters were submitted to a vote at the meeting.

## SEC filing metadata
- accession: 0001867096-23-000089
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/xers-20230607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000089
- JSON: https://secwatch.observer/filing/0001867096-23-000089.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000089.txt

## Key facts
- Shareholder Votes
  Xeris Biopharma Holdings, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows*: For Against Abstain 87,826,099 820,583 239,701
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm
- Shareholder Votes
  Xeris Biopharma Holdings, Inc. shareholders approved To elect Dawn Halkuff, John Johnson and Jeffrey Sherman as Class II directors at the 2023-06-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.